Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Study Identifier
P25-554
CT.gov Identifier
NCT07419347
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P). * Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.) * Is concomitantly on one or more prescription medications or illicit drugs.
    Exclusion Criteria:
    * Treated with DAAs other than G/P. * History of decompensated cirrhosis. * Had Hepatitis-B virus (HBV) infection. * Had hepatocellular carcinoma (HCC).

    Protocol Summary

    The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.

    Study Locations

    Location
    Status
    Location
    Vancouver Infectious Diseases Centre /ID# 275313
    Vancouver, British Columbia, Canada, V6Z 2C7
    Status
    Recruiting
    Location
    St. Clair Medical Clinic /ID# 275334
    Toronto, Ontario, Canada, M4S 1Y2
    Status
    Recruiting